Thrombo-embolic complications after Corona virus disease-19 (COVID-19) vaccination have been previously reported. We aimed to study the coronary thrombo-embolic complications (CTE) after COVID-19 vaccination in a single centre during the initial 3 months of vaccination drive in India. All patients admitted to our hospital between 1 st March 2021 and 31 st May 2021 with Acute coronary syndrome (ACS) were included. Of the 89 patients [Age 55(47-64)y,13f] with ACS and angiographic evidence of coronary thrombus, 37(42%) had prior vaccination history. The timing from last vaccination dose to index event was <1, 1-2, 2-4 and >4 weeks in 9(24%), 4(11%), 15(41%) and 9(24%) respectively. ChAdOx1 nCoV-19/AZD1222 was the most used vaccine- 28 (76%), while 9 (24%) had BBV152. Baseline characteristics were similar in both vaccinated (VG) and non-vaccinated group (NVG), except for symptom to door time [8.5(5.75-14)vs14.5(7.25-24) hrs, p=0.003]. Thrombocytopenia was not noted in any of the VG patients, while 2 (3.8%) of NVG patient had thrombocytopenia (p =0.51). The pre- Percutaneous Coronary Intervention (PCI) Thrombolysis in Myocardial Infarction (TIMI) flow was significantly lower [1(0-3)vs2(1-3), p=0.03) and thrombus grade were significantly higher [4(2.5-5)vs2(1-3), p=0.0005] in VG. The in-hospital (2.7%vs1.9%, p= 1.0) and 30-day mortality were also similar (5.4%vs5.8%, p= 1.0). This is the first report of CTE after COVID-19 vaccination during the first 3 months of vaccination drive in India. We need further reports to identify the incidence of this rare but serious adverse events following COVID-19 vaccination.